Drugs / RSV/hMPV/PIV3 formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06850051 | Mar → Dec 2025 | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/hMPV/PIV3 formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06850051 ↗ |
| Modality | Vaccine | “combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine” NCT06850051 ↗ |
| Route | Intramuscular | “Route of administration: IM injection” NCT06850051 ↗ |